Dr Jon Kay on “drift” of reference product. Lessons from Herceptin biosimilar development #eular2019 SP0014 https://t.co/uqWgYESe6N

DESIR 708 early TNFi naive axSpA finds only 36% started a TNFi & 49% switched to a 2nd TNFi & 47% to 3rd TNFi #EULAR2019 OP0012 https://t.co/5TMPofwRas

What happens when MTX-IR pts who don't respond to Adalimumab or Upadacitinib in Select compare RCT switch to other treatment? More switched out of adalimumab. Either group on average did well maybe switch to Upa a bit better but post hoc analysis. OP0029 #EULAR2019 @RheumNow https://t.co/sIG0kPPfNB

Ustekinumab in SLE, SLEDAI >=6 bilag 1A or 2B, ph2 results SRI-4 at w24 published. Sustained responses acc to SRI4, PGA, joint and CLASI to w48. Clasi even had higher response at w48. Those which switched to open label showed incremental improvement. Nice. #eular2019 @RheumNow

In a disease where there aren’t a lot of options, nintedanib reduces FVC rate of decline in SSc-ILD by >40%, independently of SSc subtype, antibody status, MMF exposure, just like it does in IPF. Breathtaking results (so to speak) #EULAR2019 Distler for SENSCIS OP0017 @RheumNow https://t.co/eRsMxc7sdr https://t.co/LyqQf5apfx

• Janet Pope on Twitter: "Good news for scleroderma lung disease. Abstract O…

New molecular pathway in RA. #EULAR2019 @RheumNow https://t.co/woTApyicbl

• Janet Pope on Twitter: "Full house in Jaki and beyond session. S Cohen pre…

Tofacitinib results in Corrona over 5 yrs vs bDMARDs. Not randomized but propensity scores showed no increased serious infection, CV events and VTE found in Tofa vs bDMARDs. Slightly more HZ. Good and reassuring safety. OP0028 #EULAR2019 @RheumNow https://t.co/8ooYWmWvfV

Hendrika Bootsma presents her ASAP III study- monocentre double blinded randomised controlled study of abatacept vs placebo also negative other than esspri response difference at w12 and w24. Extension phase study to w48 with US and histology results #eular2019 @RheumNow

No point on repeating ANA testing PPV 0.01 according to this abstract by Yeo et al. #EULAR2019 #Rheumatology @RheumNow https://t.co/kX0angBvqd

Full house in Jaki and beyond session. S Cohen presented fenebrutinib a BTK inhibitor at doses including 200 mg bid is in TNFI-IR or Mtx-IR active pts with RA in a Phase II RCT. 12 week data were similar to adalimumab. New pathway for RA Rx maybe #OP0025 https://t.co/avLSopLju6

Difficult to use existing “borrowed” conventional measures or essdai to measure change in the joint domain (most commonly affected) in abatacept study on primary Sjogren #eular2019 @RheumNow

Disappointing @tuna0sashimi: BMS abatacept 125mg wkly in Sjogren: essdai >=5 SSA+ primarily outcome mean change in essdai. Day 169 onwards open label. Negative study using these endpoints but some positive effect on serum IgG and complements. #eular2019 @RheumNow

Fantastic talk by Georgios Filippou highlighting how we can use US to help us differentiate DDx and clinical phenotypes. #eular2019 @RheumNow https://t.co/hxKqrziDSN

Empathic communication can help close the gap with patients - this is a learned skill - we need to work on it as a profession #empathy @HelenRiessMD @vmontori @JohnDavisIII @RheumNow @HealioRheum https://t.co/1pwn56o9lc

• Sanofi Genzyme on Twitter: "Join us today at #EULAR2019 for our symposium …

Romosozumab has dual effect: bone-forming AND preventing resorption. Hitting hard with this early in #osteoporosis reduces fracture risk later when on denosumab, compared to those receiving placebo prior. Similar results when patients switch to alendronate. @RheumNow #EULAR2019 https://t.co/ZSQAxSUnv9